A5078785776- Inflammatory Bowel Disease
- Microscopic Colitis
- Fibromyalgia and Chronic Fatigue Syndrome Research
- Gut microbiota and health
- Eosinophilic Esophagitis
- Autoimmune and Inflammatory Disorders
- Immunodeficiency and Autoimmune Disorders
- Autoimmune and Inflammatory Disorders Research
- Colorectal Cancer Screening and Detection
- Rheumatoid Arthritis Research and Therapies
- Dermatology and Skin Diseases
- Biosimilars and Bioanalytical Methods
- Cancer Genomics and Diagnostics
- Pregnancy and Medication Impact
- Medical Device Sterilization and Disinfection
- Psoriasis: Treatment and Pathogenesis
- Therapeutic Uses of Natural Elements
- Clostridium difficile and Clostridium perfringens research
- Helicobacter pylori-related gastroenterology studies
- Inflammasome and immune disorders
- Pharmacological Effects of Natural Compounds
- Pharmaceutical studies and practices
- Gastrointestinal motility and disorders
- Ferroptosis and cancer prognosis
- Health, psychology, and well-being
Radboud University Nijmegen
2024
Radboud University Medical Center
2024
Erasmus MC
2019-2022
Massachusetts General Hospital
2016-2021
Harvard University
2017-2020
Boston University
2017-2020
University of Groningen
2017
The older patient group with inflammatory bowel diseases (IBD) is particularly vulnerable to consequences of disease and therapy-related side effects but little known about the best treatment options in this population.To compare safety efficacy tumor necrosis factor α antagonist (anti-TNF) or vedolizumab (VDZ) patients IBD >60 years age.This retrospective study included Crohn's (CD) ulcerative colitis (UC) initiating anti-TNF VDZ therapy ≥60 age at three sites. We examined occurrence...
Abstract Backgrounds and Aims Fatigue is prevalent in patients with inflammatory bowel diseases [IBD]. Biologic therapy effective achieving symptomatic endoscopic remission, but its impact on fatigue less well established. Our aim to define the longitudinal trajectory of over 1 year initiating biologic therapy. Methods This prospective cohort enrolled diagnosed Crohn’s disease [CD] or ulcerative colitis [UC] infliximab, adalimumab, ustekinumab, vedolizumab. was quantified using seven-point...
Abstract Background Inflammatory bowel diseases (IBD) are characterized by intermittent relapses, and their course is heterogeneous unpredictable. Our aim was to determine the ability of protein, metabolite, or microbial biomarkers predict relapse in patients with quiescent disease. Methods This prospective study enrolled Crohn disease ulcerative colitis, defined as absence clinical symptoms (Harvey-Bradshaw Index ≤ 4, Simple Clinical Colitis Activity 2) endoscopic remission within prior...
Optimal treatment of inflammatory bowel disease (IBD) requires specialized health care. Patients frequently travel long distances to obtain care for IBD, which may hinder regular and affect outcomes adversely.This study included patients with established Crohn's or ulcerative colitis receiving at a single referral center between January 2005 August 2016. Distance our from the zip code residence was determined each patient classified into quartiles. Our primary outcome need IBD-related...
The long-term natural history of microscopic colitis (MC) (collagenous (CC), lymphocytic (LC)), traditionally considered relapsing but non-progressive diseases, is poorly defined. Whether persistent histologic inflammation in such diseases associated with an increased risk colorectal neoplasia (CRN) or extracolonic cancers has not been robustly established. This retrospective cohort included diagnosed MC at a referral center. Rates CRN and cancer were compared to patients undergoing...
Family history is the strongest risk factor for developing Crohn's disease [CD] or ulcerative colitis [UC]. We investigated whether proximity of relationship with affected relative and concordance type inflammatory bowel [IBD] modifies effect family on phenotype severity.This cross-sectional study included patients a confirmed diagnosis IBD in clinical registry. was assessed by questionnaire ascertaining presence first-first-degree, second-second-degree distant relative. Our primary outcomes...
Abstract Background Fatigue is a disabling symptom in patients with inflammatory bowel disease (IBD). Its prevalence, mechanism, and impact remain poorly understood. We determined changes fatigue status over time identified predictors of incident or resolving fatigue. Methods This was prospective study nested within the IBD Partners cohort. Participants prospectively completed Multidimensional Inventory Functional Assessment Chronic Illness Therapy-Fatigue at baseline, 6 months, 12 months. A...
Aims To develop and validate a new scale for mucosal visualization of the upper gastrointestinal tract during esophagogastroduodenoscopy (EGD), Gastroscopy RAte Cleanliness Evaluation (GRACE), as quality standard tool through application standardized, reliable, validated scoring system.
Emerging data highlight the critical role for innate immune system in progression of nonalcoholic fatty liver disease (NAFLD). Connexin 32 (Cx32), primary gap junction protein, is capable modulating hepatic responses and has been studied dietary animal models steatohepatitis. In this work, we sought to determine association Cx32 with stages human NAFLD a histologically characterized cohort 362 patients NAFLD. We also expression genes proteins known interact (known as connexome) Last, used...
Abstract Background Acute severe ulcerative colitis (ASUC) is a serious complication of (UC). Management partial responders to steroids or rescue therapy remains challenging. Whether there role for re-look sigmoidoscopic evaluation in disease management unknown. Methods Our study cohort consisted patients who underwent 2 procedures during the same index hospitalization ASUC at our center. Reasons repeat endoscopic and histologic severity inflammation both were noted. Multivariable regression...
Abstract Background and Aims Methotrexate [MTX] is a well-known immunomodulator in the treatment of inflammatory bowel disease [IBD] often combined with biologic agents. The ideal MTX dose for combination therapy has not been determined. This study aimed to investigate effect varying doses on efficacy safety outcomes when used anti-TNF agents IBD. Methods included patients Crohn’s [CD] or ulcerative colitis [UC] receiving care between January 2005 June 2018. Low-dose was defined as ≤12.5...